Knight Therapeutics (TSX: GUD) has announced that its new drug submission (NDS) for CREXONT—a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease—has been accepted for review by Health Canada.
According to Knight, CREXONT is expected to compete in a market size of more than $50 million in Canada and $120 million in Brazil—each market with a $15 million controlled release portion. Knight aims to submit a marketing authorization application in Mexico and Brazil this year.
Samira Sakhia, president and CEO of Knight, remarked, “The submission of CREXONT in Canada highlights Knight’s ongoing commitment to enhancing our central nervous system portfolio. With a significant unmet medical need in Parkinson’s disease treatment, CREXONT will offer a valuable new therapeutic for the patients.”
